Last reviewed · How we verify
SEVOFLURANE — Competitive Intelligence Brief
marketed
General Anesthetic [EPC]
Small molecule
Live · refreshed every 30 min
Target snapshot
SEVOFLURANE (SEVOFLURANE).
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SEVOFLURANE TARGET | SEVOFLURANE | marketed | General Anesthetic [EPC] | 1995-01-01 | ||
| Suprane | DESFLURANE | Baxter | marketed | General Anesthetic [EPC] | GABA-A receptor; anion channel | 1992-01-01 |
| Diprivan | Propofol | Fresenius Kabi | marketed | General anesthetic | GABA A receptors | 1989-01-01 |
| PROPOFOL | PROPOFOL | marketed | General Anesthetic [EPC] | 1989-01-01 | ||
| Amidate | ETOMIDATE | Pfizer | marketed | General Anesthetic [EPC] | Cytochrome P450 11B2, mitochondrial | 1982-01-01 |
| Forane | ISOFLURANE | Baxter | marketed | General Anesthetic [EPC] | 5-hydroxytryptamine receptor 2B | 1979-01-01 |
| Efrane | ENFLURANE | Baxter | marketed | General Anesthetic | Glycine receptor subunit alpha-1 | 1972-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (General Anesthetic [EPC] class)
- · 2 drugs in this class
- Baxter · 2 drugs in this class
- Pfizer · 1 drug in this class
- Pfizer Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SEVOFLURANE CI watch — RSS
- SEVOFLURANE CI watch — Atom
- SEVOFLURANE CI watch — JSON
- SEVOFLURANE alone — RSS
- Whole General Anesthetic [EPC] class — RSS
Cite this brief
Drug Landscape (2026). SEVOFLURANE — Competitive Intelligence Brief. https://druglandscape.com/ci/sevoflurane. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab